Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?

On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69.

The company reported sales of $3.72 billion, up 11%, beating the consensus of $3.67 billion.

“Regeneron had a strong third quarter marked by 11% revenue growth. We continued to deepen the impact of our commercialized medicines this quarter, with ongoing leadership for our retinal franchise, expanded global reach of Libtayo, and notable growth from Dupixent,” said Leonard S. Schleifer, Board co-Chair, President and Chief Executive Officer of Regeneron.

Also Read: Regeneron Chief Flags Health Risks with Popular Weight-Loss ...